Drug Trial Radar · NCT02297594
Safety, Tolerability and PK Study of AK0529 in Healthy Human
Last checked: Nov 20, 2026Latest source record: Oct 20, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
74
Actual
Start
Oct 2014
Primary completion
Jun 2015
Study completion Jun 2015
Sponsor
- Lead sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 21, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, tolerability and PK of single and multiple ascending dose of AK0529 when administered orally in healthy subjects
Conditions
- Respiratory Syncytial Virus Infections
Interventions
AK0529Drug
AK0529 capsule for oral administration
PlaceboDrug
Sugar placebo capsule for oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events, serious adverse eventsTime frame: Screening to Day 14 - 21
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Q-Pharm Pty Ltd QIMR Berghofer & Royal Brisbane and Women's Hospital Campus
Brisbane, Queensland, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.